Novel Oral Anticoagulants for Preventing Stroke in Patients with Atrial Fibrillation

January 22, 2015 | Technology Forecasts


Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 3 (Expected to be used by 40% to 60% of eligible patients)

The substantial cost differential between Factor Xa (FXa) inhibitors and warfarin could limit widespread use of this drug class for some patients. However, use of FXa inhibitors would be expected to increase as more drugs in this class enter the market and introduce greater price competition.

Estimated Adoption Status: 4 (Middle adoption – 25% to 75%...

Access Full Content

Contact us today at 610.825.6000.